<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pediatr Nephrol</journal-id>
      <journal-title>Pediatric Nephrology (Berlin, Germany)</journal-title>
      <issn pub-type="ppub">0931-041X</issn>
      <issn pub-type="epub">1432-198X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17216262</article-id>
      <article-id pub-id-type="pmc">1794138</article-id>
      <article-id pub-id-type="publisher-id">357</article-id>
      <article-id pub-id-type="doi">10.1007/s00467-006-0357-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Educational Feature</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pathophysiology of focal segmental glomerulosclerosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reidy</surname>
            <given-names>Kimberly</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Kaskel</surname>
            <given-names>Frederick J.</given-names>
          </name>
          <address>
            <email>fkaskel@aecom.yu.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Division of Pediatric Nephrology, Children&#x2019;s Hospital at Montefiore, Bronx, NY 10467 USA </aff>
        <aff id="Aff2"><label>2</label>Division of Pediatric Nephrology, Children&#x2019;s Hospital at Montefiore, 111 East 210th St., Bronx, NY 10467 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>1</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2007</year>
      </pub-date>
      <volume>22</volume>
      <issue>3</issue>
      <fpage>350</fpage>
      <lpage>354</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>6</month>
          <year>2006</year>
        </date>
        <date date-type="rev-recd">
          <day>1</day>
          <month>8</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>8</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; IPNA 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Focal segmental glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage kidney disease (ESKD). In recent years, animal models and studies of familial forms of nephrotic syndrome helped elucidate some mechanisms of podocyte injury and disease progression in FSGS. This article reviews some of the experimental and clinical data on the pathophysiology of FSGS.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Focal segmental glomerulosclerosis (FSGS)</kwd>
        <kwd>Nephrotic syndrome</kwd>
        <kwd>Pathophysiology</kwd>
        <kwd>Podocyte</kwd>
        <kwd>Injury</kwd>
        <kwd>Animal models</kwd>
        <kwd>Nephrin</kwd>
        <kwd>Podocin</kwd>
        <kwd>Transforming growth factor (TGF&#x3B2;)</kwd>
        <kwd>Tubulointerstitial</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; IPNA 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <p><bold>Learning objectives</bold> <list list-type="bullet"><list-item><p>Discuss the experimental and clinical data on the pathophysiology of FSGS</p></list-item><list-item><p>Review the alterations in glomerular structure and function associated with FSGS</p></list-item><list-item><p>To identify potential mechanisms responsible for disease progression in FSGS</p></list-item><list-item><p>Distinguish some targets for the future therapy of FSGS</p></list-item></list></p>
    <p>Focal segmental glomerulosclerosis (FSGS) is a disease entity defined by findings on kidney biopsy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. FSGS is the major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) in children and adults [<xref ref-type="bibr" rid="CR3">3</xref>]. FSGS is the most common cause of acquired chronic renal insufficiency in children and frequently leads to progression to end-stage kidney disease (ESKD) [<xref ref-type="bibr" rid="CR2">2</xref>]. FSGS may occur secondary to such disparate disease processes as HIV and obesity [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]; this review focuses on the pathophysiology of primary FSGS (i.e., with no underlying illness).</p>
    <p>Alterations of normal glomerular structure and function have been found in FSGS [<xref ref-type="bibr" rid="CR5">5</xref>]. Normal function requires that the three major components of the glomerular filter (the endothelial cells, podocytes, and glomerular basement membrane) are intact and are able to provide a permselective filtration barrier (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Specialized tight junctions between podocyte foot processes create the slit diaphragm which is integral to preventing the loss of protein into the urinary space [<xref ref-type="bibr" rid="CR6">6</xref>]. While the clinical presentation of FSGS is often heterogeneous, a characteristic feature of the disease is proteinuria, which implies the loss of this barrier [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Indeed, electron microscopy has shown distortion of the normal architecture (or effacement) of the foot processes of podocytes in FSGS [<xref ref-type="bibr" rid="CR1">1</xref>]. The connection between these projections of the epithelial cell and the underlying basement membrane can be disrupted, leading to the loss of nonspecific plasma proteins into the tubular filtrate [<xref ref-type="bibr" rid="CR6">6</xref>].
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p><bold>A</bold> Components of the normal glomerular filtration barrier: (1) glomerular basement membrane (GBM); (2) podocyte foot process; (3) endothelial cell; <bold>B</bold> Progressive changes seen in focal segmental glomerulosclerosis (FSGS) leading to sclerosis: (1) foot process effacement; (2) podocyte apoptosis/loss and exposed glomerular basement membrane; (3) filtration of non-specific plasma proteins; (4) capillary expansion; (5) formation of synechiae; (6) misdirected filtration at points of synechiae; (7) mesangial matrix proliferation. Adapted from Kwoh et al. [<xref ref-type="bibr" rid="CR9">9</xref>]</p></caption><graphic position="anchor" xlink:href="467_2006_357_Fig1_HTML" id="MO1"/></fig></p>
    <p>However, unlike other causes of proteinuria and nephrotic syndrome, such as minimal change disease (MCD), FSGS often progresses to ESKD. While foot process effacement is seen in MCD as well as FSGS, histologically, FSGS is characterized by increased extracellular matrix within the glomerular tuft with obliteration of the glomerular capillary lumen. These sclerotic lesions occur focally and in only some segments of glomeruli, and are typically not associated with immune complex deposition [<xref ref-type="bibr" rid="CR1">1</xref>]. The location of sclerotic lesions by light microscopy defines the variants of FSGS: perihilar variant (with sclerosis of the vascular pole), cellular variant (associated with hypercellularity of the capillary space), tip variant (involving the part of the glomerulus near the origin of the proximal tubule), and collapsing variant (with one or more glomeruli with global or segmental collapse) [<xref ref-type="bibr" rid="CR1">1</xref>]. Clinically, the variants of FSGS differ; for example, the collapsing variant tends to progress more rapidly to ESKD and commonly occurs in the setting of HIV [<xref ref-type="bibr" rid="CR1">1</xref>]. It is possible that different mechanisms may play a role in the pathogenesis of each variant of FSGS [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
    <p>Insight into the pathogenesis of FSGS developed over the past decade from studies of genetic mutations in mice, models of progressive glomerulosclerosis (such as the rat remnant kidney model), and identification of gene mutations in some familial forms of nephrotic syndrome (including congenital nephrotic syndrome and familial and autosomal dominant FSGS) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
    <p>Key in the pathogenesis of FSGS is podocyte damage and loss [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Injury to podocytes occurs by four major mechanisms: alteration of the components of the slit diaphragm or interference with its structure, dysregulation of the actin cytoskeleton, alteration of the glomerular basement membrane or its interactions with the podocyte, or alteration of the negative surface charge of the podocyte [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Damage to podocytes triggers apoptosis and their detachment of podocytes from the glomerular basement membrane [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The ensuing reduction in podocyte number is felt to play an important role in the pathogenesis of FSGS [<xref ref-type="bibr" rid="CR7">7</xref>]. The podocyte is normally a terminally differentiated cell with limited proliferative capacity in response to injury [<xref ref-type="bibr" rid="CR7">7</xref>]. The initial insult to the podocyte leads to further damage mediated by cytokine release, mechanical stress, and further loss of polarity, resulting in sclerosis and scarring of the glomerulus [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p>
    <p>Genetic mutations seen in congenital forms of nephrotic syndrome and FSGS enabled researchers to identify specific gene mutations involved in podocyte damage [<xref ref-type="bibr" rid="CR10">10</xref>]. Mutations of the nephrin gene, a podocyte-specific transmembrane component of the slit diaphragm, are found in congenital Finnish-type nephrotic syndrome, and may lead to loss of normal caliber slit diaphragms [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>]. In mouse models, mutations of nephrin-like transmembrane genes (<italic>NEPH-1</italic>) which also localize to the slit diaphragm result in proteinuria and early death [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
    <p>It is unclear how alteration of the slit diaphragm results in podocyte loss. The slit diaphragm may be integral to maintaining cell polarity or its damage may alter the balance of cell signals, resulting in apoptosis. Mutations in a Fyn kinase (one of the src tyrosine kinases) that phosphorylates nephrin and may regulate cell cycle and apoptosis resulted in proteinuria and foot process effacement in a mouse model [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
    <p>Other proteins which are part of the slit diaphragm complex include: podocin, CD2-associated protein (CD2AP), FAT, ZO-1, P-cadherin, an LAP (leucine rich repeat and PDZ domain) protein, and MAGI-1 [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Mutations in podocin (a transmembrane protein that interacts with nephrin, NEPH-1 and CD2AP) have been identified in familial FSGS [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Recently, mutations in CD2AP, an immunoglobulin-like protein that is involved in nephrin integration with the podocyte cytoskeleton, have also been linked to genetic forms of FSGS [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In mouse models, the loss of FAT1 and FAT2 (transmembrane proteins with cadherin-like repeats) results in the absence of slit diaphragms, proteinuria, and early death [<xref ref-type="bibr" rid="CR10">10</xref>]. The role of the other components of the slit diaphragm in the pathophysiology of FSGS is not yet clear.</p>
    <p>Alpha-actinin-4, an important structural component of the podocyte cytoskeleton, is mutated in some autosomal dominant forms of FSGS [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>]. Other mutations have been identified in association with FSGS in addition to abnormal structural proteins. For example, TRPC6 is a cation-selective ion-channel protein that mediates calcium signals and has also been associated with FSGS [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
    <p>Certain clinical variants of FSGS are suggestive of different mechanisms of injury to the podocyte. For example, a circulating factor which leads to glomerular basement membrane injury has been proposed in the pathogenesis of some types of FSGS [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. For example, there appears to be a role of a circulatory factor in the recurrence of FSGS in transplanted kidneys [<xref ref-type="bibr" rid="CR20">20</xref>]. In some patients with recurrent FSGS, proteinuria remits in response to plasmapheresis and the removal of serum proteins. In addition, injections of serum from patients with recurrent FSGS were capable of inducing proteinuria in rats [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
    <p>Another example of alternative mechanisms of injury is collapsing FSGS, which occurs in the setting of viruses such as HIV. In collapsing FSGS, dysregulation of the podocyte cell cycle appears to result in immature, proliferative podocytes [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Finally, recent work has focused on the role of the parietal epithelial cell in the pathophysiology of FSGS [<xref ref-type="bibr" rid="CR23">23</xref>]. Proliferation of parietal epithelial cells was identified in both a transgenic model of FSGS and a biopsy from a patient with collapsing FSGS [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
    <p>Of great clinical importance is the mechanism by which the initial podocyte injury progresses to the final sclerotic lesion (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). As podocyte numbers decline, there is a relative exposure of the glomerular basement membrane. Maladaptive interactions develop between the glomerular basement membrane and the parietal epithelial cells. Expansion of synechiae and/or the leak of protein into Bowman&#x2019;s space results in the deposition of collagen. Ultimately, this results in the collapse of the capillary loop and the loss of endothelial cells [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
    <p>Factors resulting in the progression of FSGS to ESKD have also been the focus of recent research (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Cytokines and vasoactive factors are believed to play a major role in the progression of FSGS. The overexpression of transforming growth factor &#x3B2; (TGF&#x3B2;) or its effector proteins, the Smads, leads to glomerulosclerosis in animal models [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Activation of the renin-angiotensin system upregulates TGF&#x3B2; and is felt to further lead to the progression of disease [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Other angiogenic factors, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) may also play a role in disease progression [<xref ref-type="bibr" rid="CR24">24</xref>]. The evidence for this is primarily based on animal models of progressive glomerulosclerosis, such as the rat remnant kidney model. In this model, PDGF and VEGF are upregulated and the later loss of VEGF expression correlates with progression of the glomerulosclerosis [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Factors involved in the progression of FSGS to end-stage kidney disease (ESKD): initial loss or injury to podocytes (related to defects in membrane proteins or cytoskeleton instability) leads to cytokine release, mechanical stress, hyperfiltration, and glomerular hypertrophy. These factors lead to upregulation of an inflammatory response mediated by monocytes, macrophages, and T-cells. The end result is collagen matrix deposition and fibrosis, and progression to ESKD</p></caption><graphic position="anchor" xlink:href="467_2006_357_Fig2_HTML" id="MO2"/></fig></p>
    <p>Mechanical stress is also believed to play a role in the progression of FSGS [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Increased filtration due the defects of the filtration barrier results in increased single-nephron glomerular filtration rate (SNGFR). This hyperfiltration results in hypertrophy of glomeruli. The hypertrophy exacerbates the mismatch between the glomerular basement membrane and the decreased numbers of podocytes, resulting in further injury [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
    <p>Another factor in the progression of FSGS is tubulointerstitial injury. Clinically, tubulointerstitial injury is a predictor of the loss of renal function in FSGS [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The nonspecific entry of proteins into the tubular lumen is one potential source of damage to the interstitium. Indeed, persistence of nephrotic-range proteinuria is a negative prognostic factor for the progression of FSGS to ESKD [<xref ref-type="bibr" rid="CR28">28</xref>]. While it is unclear if proteinuria itself is toxic to the tubulointerstitium, decreases in proteinuria achieved by angiotensin-converting enzyme (ACE) inhibitors and by angiotensin receptor blockers (ARB) appear to slow disease progression in some adults with FSGS [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p>
    <p>The presence of plasma proteins in the tubular filtrate may directly injure the tubulointerstitium. Cytokines (such as TGF&#x3B2;), when present in the tubules, will recruit monocytes, macrophage, and T-cells. This stimulates other cytokines, including interleukin-1, tumor necrosis factor alpha, and other chemokines [<xref ref-type="bibr" rid="CR24">24</xref>]. The inflammatory infiltrate leads to mesangial matrix deposition, promoting the collapse of glomeruli. The cellular infiltrate and cytokines also damage tubular epithelial cells, and some tubular epithelial cells may undergo transformation to mesenchymal cells (an epithelial-mesenchymal transition or EMT) [<xref ref-type="bibr" rid="CR24">24</xref>]. These mesenchymal cells, as well as recruited and stimulated fibroblasts, result in collagen matrix deposition and tubulointerstitial fibrosis [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
    <p>The beneficial effects of blocking the renin-angiotensin system may not be limited to their antiproteinuric or antihypertensive effects. As noted earlier, angiotensin stimulates TGF&#x3B2;, contributing to fibrosis. It can also induce oxidative stress and it is stimulated by mechanical stress, such as hyperfiltration [<xref ref-type="bibr" rid="CR24">24</xref>]. In addition, angiotensin affects intracellular calcium concentrations and the podocyte cytoskeleton [<xref ref-type="bibr" rid="CR24">24</xref>]. Inhibition of angiotensin may slow progression by these local mechanisms [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p>
    <p>With the increasing incidence of FSGS in children [<xref ref-type="bibr" rid="CR30">30</xref>], these pathways of podocyte injury and disease progression provide important targets for future intervention. Trials have already been initiated to antagonize cytokines, such as TGF&#x3B2;. Future therapeutic targets may include factors involved in podocyte protection or tubulointerstitial injury.</p>
    <p><bold>Questions</bold> (Answers appear following the reference list)
<list list-type="order"><list-item><p>Which of the following statements is TRUE regarding the current understanding of the pathogenesis of focal segmental glomerulosclerosis (FSGS)? 
<list list-type="alpha-lower"><list-item><p>FSGS may result from immune-complex-mediated damage to endothelial cells</p></list-item><list-item><p>Alterations in components of the slit diaphragm may play a role in the pathogenesis of FSGS</p></list-item><list-item><p>Proliferation of podocytes leads to cytokine release and mechanical stress, resulting in scarring and sclerosis of the glomeruli</p></list-item><list-item><p>Mutations in a chloride channel have been associated with FSGS and may be pathogenic</p></list-item></list></p></list-item><list-item><p>All of the following are mutations of structural proteins that have been identified as pathogenic in FSGS EXCEPT: 
<list list-type="alpha-lower"><list-item><p>Sodium channel mutation</p></list-item><list-item><p>Alpha-actinin-4</p></list-item><list-item><p>Nephrin</p></list-item><list-item><p>Podocin</p></list-item></list></p></list-item><list-item><p>Progression of FSGS to end-stage kidney disease (ESKD) results from: 
<list list-type="alpha-lower"><list-item><p>Downregulation of transforming growth factor &#x3B2; (TGF&#x3B2;)</p></list-item><list-item><p>Decreased glomerular filtration</p></list-item><list-item><p>Tubulointerstitial injury</p></list-item><list-item><p>Blockade of the renin-angiotensin system</p></list-item></list></p></list-item><list-item><p>Proteinuria in the setting of FSGS: 
<list list-type="alpha-lower"><list-item><p>Has no effect on clinical course</p></list-item><list-item><p>May be decreased by treatment with angiotensin-converting enzyme (ACE) inhibitors</p></list-item><list-item><p>Results from an increased number of glomerular foot processes</p></list-item><list-item><p>Leads to the loss of mesangial matrix</p></list-item></list></p></list-item><list-item><p>Which of the following is FALSE: 
<list list-type="alpha-lower"><list-item><p>A circulating factor may play a role in the pathogenesis of FSGS</p></list-item><list-item><p>Proliferation of parietal epithelial cells has been identified in collapsing FSGS</p></list-item><list-item><p>Podocyte loss due to necrosis appears to play a role in the pathogenesis of FSGS</p></list-item><list-item><p>CD2-associated protein, FAT, nephrin, and podocin are examples of slit diaphragm proteins</p></list-item></list></p></list-item></list></p>
  </body>
  <back>
    <!-- WARNING: ArticleNote has not been converted -->
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#x2019;Agati</surname>
              <given-names>VD</given-names>
            </name>
          </person-group>
          <article-title>Pathologic classification of focal segmental glomerulosclerosis</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>117</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50012</pub-id>
        </citation>
        <citation citation-type="display-unstructured">D&#x2019;Agati VD (2003) Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 23(2):117&#x2013;134 <pub-id pub-id-type="pmid">12704572</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schnaper</surname>
              <given-names>HW</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic focal segmental glomerulosclerosis</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>183</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50016</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schnaper HW (2003) Idiopathic focal segmental glomerulosclerosis. Semin Nephrol 23(2):183&#x2013;193 <pub-id pub-id-type="pmid">12704578</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dingli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Plevak</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Grande</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Focal and segmental glomerulosclerosis and plasma cell proliferative disorders</article-title>
          <source>Am J Kidney Dis</source>
          <year>2005</year>
          <volume>46</volume>
          <issue>2</issue>
          <fpage>278</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="doi">10.1053/j.ajkd.2005.05.004</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA (2005) Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 46(2):278&#x2013;282 <pub-id pub-id-type="pmid">16112046</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kambham</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Markowitz</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Valeri</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>D&#x2019;Agati</surname>
              <given-names>VD</given-names>
            </name>
          </person-group>
          <article-title>Obesity-related glomerulopathy: an emerging epidemic</article-title>
          <source>Kidney Int</source>
          <year>2001</year>
          <volume>59</volume>
          <issue>4</issue>
          <fpage>1498</fpage>
          <lpage>1509</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2001.0590041498.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kambham N, Markowitz GS, Valeri AM, Lin J, D&#x2019;Agati VD (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59(4):1498&#x2013;1509 <pub-id pub-id-type="pmid">11260414</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kriz</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>The pathogenesis of &#x201C;classic&#x201D; focal segmental glomerulosclerosis&#x2014;lessons from rat models</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2003</year>
          <volume>18</volume>
          <issue>Suppl 6</issue>
          <fpage>vi39</fpage>
          <lpage>vi44</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kriz W (2003) The pathogenesis of &#x201C;classic&#x201D; focal segmental glomerulosclerosis&#x2014;lessons from rat models. Nephrol Dial Transplant 18(Suppl 6):vi39&#x2013;vi44 <pub-id pub-id-type="pmid">12953041</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asanuma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mundel</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The role of podocytes in glomerular pathobiology</article-title>
          <source>Clin Exp Nephrol</source>
          <year>2003</year>
          <volume>7</volume>
          <issue>4</issue>
          <fpage>255</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="doi">10.1007/s10157-003-0259-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Asanuma K, Mundel P (2003) The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 7(4):255&#x2013;259 <pub-id pub-id-type="pmid">14712353</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fogo</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Animal models of FSGS: lessons for pathogenesis and treatment</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>161</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50015</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fogo AB (2003) Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 23(2):161&#x2013;171 <pub-id pub-id-type="pmid">12704576</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyrier</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>E pluribus unum: the riddle of focal segmental glomerulosclerosis</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>135</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50013</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Meyrier A (2003) E pluribus unum: the riddle of focal segmental glomerulosclerosis. Semin Nephrol 23(2):135&#x2013;140 <pub-id pub-id-type="pmid">12704573</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwoh</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Miner</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis of nonimmune glomerulopathies</article-title>
          <source>Annu Rev Pathol Mech Dis</source>
          <year>2006</year>
          <volume>1</volume>
          <fpage>349</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100119</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kwoh C, Shannon MB, Miner JH, Shaw A (2006) Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol Mech Dis 1:349&#x2013;374 </citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tryggvason</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Patrakka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wartiovaara</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Hereditary proteinuria syndromes and mechanisms of proteinuria</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>354</volume>
          <issue>13</issue>
          <fpage>1387</fpage>
          <lpage>1401</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra052131</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tryggvason K, Patrakka J, Wartiovaara J (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354(13):1387&#x2013;1401 <pub-id pub-id-type="pmid">16571882</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kestila</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lenkkeri</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Mannikko</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lamerdin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McCready</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Putaala</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ruotsalainen</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Morita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nissinen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Herva</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kashtan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Peltonen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tryggvason</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Positionally cloned gene for a novel glomerular protein&#x2014;nephrin&#x2014;is mutated in congenital nephrotic syndrome</article-title>
          <source>Mol Cell</source>
          <year>1998</year>
          <volume>1</volume>
          <issue>4</issue>
          <fpage>575</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="doi">10.1016/S1097-2765(00)80057-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan C, Peltonen L, Holmberg C, Olsen A, Tryggvason K (1998) Positionally cloned gene for a novel glomerular protein&#x2014;nephrin&#x2014;is mutated in congenital nephrotic syndrome. Mol Cell 1(4):575&#x2013;582 <pub-id pub-id-type="pmid">9660941</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karle</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Uetz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ronner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Glaeser</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fuchshuber</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2002</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>388</fpage>
          <lpage>393</lpage>
        </citation>
        <citation citation-type="display-unstructured">Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A (2002) Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13(2):388&#x2013;393 <pub-id pub-id-type="pmid">11805166</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shih</surname>
              <given-names>NY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Karpitskii</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dustin</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kanagawa</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Miner</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Congenital nephrotic syndrome in mice lacking CD2-associated protein</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>286</volume>
          <issue>5438</issue>
          <fpage>312</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1126/science.286.5438.312</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS (1999) Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286(5438):312&#x2013;315 <pub-id pub-id-type="pmid">10514378</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Winkler</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Kopp</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Miner</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Unanue</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility</article-title>
          <source>Science</source>
          <year>2003</year>
          <volume>300</volume>
          <issue>5623</issue>
          <fpage>1298</fpage>
          <lpage>1300</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1081068</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, Unanue ER, Shaw AS (2003) CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300(5623):1298&#x2013;1300 <pub-id pub-id-type="pmid">12764198</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghiggeri</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Artero</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carraro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Perfumo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2001</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>882</fpage>
          <lpage>885</lpage>
          <pub-id pub-id-type="doi">10.1093/ndt/16.5.882</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ghiggeri GM, Artero M, Carraro M, Perfumo F (2001) Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor. Nephrol Dial Transplant 16(5):882&#x2013;885 <pub-id pub-id-type="pmid">11328888</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaplan</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>North</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Rennke</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>HQ</given-names>
            </name>
            <name>
              <surname>Mathis</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Rodriguez-Perez</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Beggs</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Pollak</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>24</volume>
          <issue>3</issue>
          <fpage>251</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="doi">10.1038/73456</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24(3):251&#x2013;256 <pub-id pub-id-type="pmid">10700177</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Kos</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Denker</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Pollak</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein</article-title>
          <source>PLoS Biol</source>
          <year>2004</year>
          <volume>2</volume>
          <issue>6</issue>
          <fpage>787</fpage>
          <lpage>794</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.pbio.0020167</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR (2004) Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2(6):787&#x2013;794 </citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winn</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Conlon</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Lynn</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Farrington</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Creazzo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Daskalakis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ebersviller</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Burchette</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pericak-Vance</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Howell</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>PB</given-names>
            </name>
          </person-group>
          <article-title>A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis</article-title>
          <source>Science</source>
          <year>2005</year>
          <volume>17</volume>
          <issue>5729</issue>
          <fpage>1801</fpage>
          <lpage>1804</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1106215</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB (2005) A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 17(5729):1801&#x2013;1804 <pub-id pub-id-type="pmid">15879175</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Savin</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>McCarthy</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Permeability factors in focal segmental glomerulosclerosis</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>147</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50024</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Savin VJ, McCarthy ET, Sharma M (2003) Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 23(2):147&#x2013;160 <pub-id pub-id-type="pmid">12704575</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daskalakis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Winn</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
          <article-title>Focal and segmental glomerulosclerosis: varying biologic mechanisms underlie a final histopathologic end point</article-title>
          <source>Semin Nephrol</source>
          <year>2006</year>
          <volume>26</volume>
          <issue>2</issue>
          <fpage>89</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1016/j.semnephrol.2005.09.001</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Daskalakis N, Winn MP (2006) Focal and segmental glomerulosclerosis: varying biologic mechanisms underlie a final histopathologic end point. Semin Nephrol 26(2):89&#x2013;94 <pub-id pub-id-type="pmid">16530601</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barisoni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kriz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mundel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>D&#x2019;Agati</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy</article-title>
          <source>J Am Soc Nephrol</source>
          <year>1999</year>
          <volume>10</volume>
          <issue>1</issue>
          <fpage>51</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="doi">10.1159/000017097</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Barisoni L, Kriz W, Mundel P, D&#x2019;Agati V (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10(1):51&#x2013;61 <pub-id pub-id-type="pmid">9890309</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwimmer</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Markowitz</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Valeri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Appel</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Collapsing glomerulopathy</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>209</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50019</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schwimmer JA, Markowitz GS, Valeri A, Appel GB (2003) Collapsing glomerulopathy. Semin Nephrol 23(2):209&#x2013;218 <pub-id pub-id-type="pmid">12704581</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dijkman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Smeets</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Laak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Steenbergen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wetzels</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis</article-title>
          <source>Kidney Int</source>
          <year>2005</year>
          <volume>68</volume>
          <issue>4</issue>
          <fpage>1562</fpage>
          <lpage>1572</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00568.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dijkman H, Smeets B, van der Laak J, Steenbergen E, Wetzels J (2005) The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int 68(4):1562&#x2013;1572 <pub-id pub-id-type="pmid">16164633</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Neilson</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Toward a unified theory of renal progression</article-title>
          <source>Annu Rev Med</source>
          <year>2006</year>
          <volume>57</volume>
          <fpage>365</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.med.57.121304.131342</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harris RC, Neilson EG (2006) Toward a unified theory of renal progression. Annu Rev Med 57:365&#x2013;380 <pub-id pub-id-type="pmid">16409155</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Joly</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>S-W</given-names>
            </name>
            <name>
              <surname>Hugo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kerjaschki</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Mazzali</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jefferson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Madsen</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Schreiner</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2001</year>
          <volume>12</volume>
          <issue>7</issue>
          <fpage>1434</fpage>
          <lpage>1447</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kang DH, Joly AH, Oh S-W, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ (2001) Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12(7):1434&#x2013;1447 <pub-id pub-id-type="pmid">11423572</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hostetter</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
          <article-title>Hyperfiltration and glomerulosclerosis</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>194</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="doi">10.1053/anep.2003.50017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hostetter TH (2003) Hyperfiltration and glomerulosclerosis. Semin Nephrol 23(2):194&#x2013;199 <pub-id pub-id-type="pmid">12704579</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez-Iturbe</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Herrera-Acosta</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Tubulointerstitial damage and progression of renal failure</article-title>
          <source>Kidney Int</source>
          <year>2005</year>
          <volume>68</volume>
          <issue>Supp 99</issue>
          <fpage>S82</fpage>
          <lpage>S86</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.09915.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J (2005) Tubulointerstitial damage and progression of renal failure. Kidney Int 68(Supp 99):S82&#x2013;S86 </citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walls</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Relationship between proteinuria and progressive renal disease</article-title>
          <source>Am J Kidney Dis</source>
          <year>2001</year>
          <volume>37</volume>
          <issue>1 Supp 2</issue>
          <fpage>S13</fpage>
          <lpage>S16</lpage>
        </citation>
        <citation citation-type="display-unstructured">Walls J (2001) Relationship between proteinuria and progressive renal disease. Am J Kidney Dis 37(1 Supp 2):S13&#x2013;S16 <pub-id pub-id-type="pmid">11158854</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Korbet</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis</article-title>
          <source>Semin Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>219</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="doi">10.1053/snep.2003.50020</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Korbet SM (2003) Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 23(2):219&#x2013;228 <pub-id pub-id-type="pmid">12704582</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Filler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Geier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Drukker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feber</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Is there really an increase in non-minimal change nephrotic syndrome in children?</article-title>
          <source>Am J Kidney Dis</source>
          <year>2003</year>
          <volume>42</volume>
          <issue>6</issue>
          <fpage>1107</fpage>
          <lpage>1113</lpage>
          <pub-id pub-id-type="doi">10.1053/j.ajkd.2003.08.010</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J (2003) Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis 42(6):1107&#x2013;1113 <pub-id pub-id-type="pmid">14655180</pub-id></citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>KR is a Pediatric Nephrology Trainee supported by grant no. NIH T32 DK007110 30. FJK is supported in part by NIH DK63549-04.</p>
      </fn>
      <fn>
        <p><bold>Answers</bold> <list list-type="order"><list-item><p>B</p></list-item><list-item><p>A</p></list-item><list-item><p>C</p></list-item><list-item><p>B</p></list-item><list-item><p>C</p></list-item></list></p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>